

## Special Issue

# FtsZ and RnpA as Valid Targets while Developing Novel Antimicrobials

### Message from the Guest Editor

Antimicrobial resistance is a serious problem for public health. Investigating innovative antibacterial targets could be a favorable way to counteract this issue. In the last decade two important proteins have started being considered and exploited, due to their crucial role in bacterial viability and to their established druggability: FtsZ and RnpA. Both FtsZ and RnpA are widely conserved among the highest priority pathogens and have limited to null homology with eukaryotic proteins, hoping for broad-spectrum antimicrobials with low cytotoxicity on human cells. This Issue would invite all researchers involved in fighting antimicrobial resistance by studying FtsZ and RnpA with different perspectives and positions. All manuscripts dealing with the design, synthesis, and the biological evaluation of novel antimicrobials targeting FtsZ and RnpA are welcome, as well as papers developing computational models, innovative assays, target-ligand characterization, crystallographic structures and biological mechanisms related to these two proteins. **Keywords:** FtsZ inhibitors, RnpA inhibition, bacteriostatic effect, bacterial cell division process, mRNA turnover

### Guest Editor

Dr. Valentina Straniero

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Luigi Mangiagalli, 25, 20133 Milan, Italy

### Deadline for manuscript submissions

closed (31 January 2021)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/44708](https://mdpi.com/si/44708)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)